BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed

BIOVIE INC.

Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.
Apparent reduction in amyloid burden: 36.5% of PrecivityAD-positive patients reverted to negative after 30 weeks.
Significant increases in insulin and beta cell function (HOMA2-%B +13.5%, p<0.0001) without hypoglycemia.
FDG-PET SUVRs increased in 10 of 21 sub-study patients, suggesting reduced amyloid burden.
Company expects unblinded topline data in late November or early December 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.